Legler U F
Horm Metab Res. 1987 Apr;19(4):168-70. doi: 10.1055/s-2007-1011769.
This study was undertaken to determine the pharmacokinetics of intravenous prednisolone in patients with Graves' eye disease. 6 women with Graves' ophthalmopathy treated with prednisolone for severe endocrine exophthalmos were compared with 6 healthy female volunteers. All subjects with Graves' disease had been taking carbimazole and I-thyroxine as concurrent drugs for at least 4 months prior to study day. All subjects were euthyroid. Each subject received .54 mg/kg prednisolone as an i.v. bolus. Plasma concentrations for total and unbound prednisolone were determined by HPLC and equilibrium dialysis. Significant increase (p less than .01) in clearance values and significant decreases in half-life times (p less than .01) were found for both total and unbound prednisolone in women with Graves' disease compared with the control subjects. Volumes of distribution at steady-state were unchanged in both groups. The data suggest that patients with Graves' ophthalmopathy show an enhanced elimination for prednisolone and that is why they may need higher doses of corticoid although the function of the thyroid gland is euthyroid.
本研究旨在确定静脉注射泼尼松龙在格雷夫斯眼病患者中的药代动力学。将6例因严重内分泌性突眼而接受泼尼松龙治疗的格雷夫斯眼眶病女性患者与6名健康女性志愿者进行比较。所有格雷夫斯病患者在研究日前至少4个月一直将卡比马唑和左旋甲状腺素作为同时服用的药物。所有受试者甲状腺功能正常。每位受试者静脉推注0.54 mg/kg泼尼松龙。通过高效液相色谱法和平衡透析法测定总泼尼松龙和游离泼尼松龙的血浆浓度。与对照组相比，格雷夫斯病女性患者的总泼尼松龙和游离泼尼松龙清除率值显著增加（p<0.01），半衰期显著缩短（p<0.01）。两组的稳态分布容积均未改变。数据表明，格雷夫斯眼眶病患者对泼尼松龙的消除增强，这就是为什么尽管甲状腺功能正常，他们可能仍需要更高剂量的皮质类固醇。
